Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Tempus AI TEM has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca AZN ...

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and ...

Tempus AI Inc (NASDAQ:TEM) shares closed up 14.5% following the announcement of expanded strategic partnerships with ...

Amid a bullish backdrop for the broader market, Tempus AI ( TEM 7.97%) stock is posting big gains Wednesday. The company's share price was up 15.8% as of 1:45 p.m. ET. At the same point in time, the S ...

The share price of health technology company Tempus AI (NASDAQ: TEM) has soared by double digits, fueled by positive investor ...

Tempus stands to earn $200 million in data licensing and model development fees from the collaborations, the release said.

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...

With markets showing signs of life again, some of the most oversold stocks are going along for the ride. That includes ...

Tempus AI has reported impressive growth, but some of the volatile quarterly numbers have chased off aggressive investors.